Stadol, the brand-name version of butorphanol nasal spray, was discontinued by its manufacturer as a business decision, not because the FDA pulled it from the market for safety reasons. The drug itself remains available as a generic. However, the story behind Stadol’s rise and fall is largely one of widespread abuse and diversion that fundamentally changed how the medication was regulated and prescribed.
What Stadol Was Used For
Stadol nasal spray launched in 1992 as a novel pain reliever. Butorphanol, its active ingredient, works differently from standard opioids. It has mixed activity at the brain’s opioid receptors, acting as a partial blocker at one type (mu receptors) while activating another (kappa receptors). This unusual profile was supposed to make it less addictive than full opioids like morphine or codeine while still providing strong pain relief.
The nasal spray format was a big part of its appeal. Patients could self-administer it at home for acute pain, and it became especially popular for migraine treatment. Unlike an injection, it was portable and fast-acting. For migraine sufferers who couldn’t keep oral medications down during an attack, a nasal spray was a practical option. Some state prescribing guidelines required that patients try preventive migraine therapy and triptans before being approved for butorphanol, positioning it as a second- or third-line treatment rather than a first choice.
The Abuse Problem That Changed Everything
The injectable form of butorphanol had been on the market for years before the nasal spray, with only limited abuse among certain populations. That changed dramatically once the spray became available. The ease of use that made it attractive for legitimate patients also made it attractive for misuse.
By the mid-1990s, the DEA was receiving abuse reports from 44 states. An FDA survey of state drug program directors and pharmacy boards found that 83% of respondents were aware of non-medical use, diversion, or abuse of butorphanol in their state. The nasal spray was the primary concern: 74% of states reported abuse of the spray form compared to 52% for the injectable. About 60% of states identified overprescribing as the main source of diverted drugs, while 55% pointed to forged or altered prescriptions.
The scope of the problem prompted the National Association of State Controlled Substances Authorities to pass a resolution in November 1996 urging the FDA and DEA to schedule butorphanol as a controlled substance. By 1997, the DEA proposed placing butorphanol into Schedule IV of the Controlled Substances Act, a category that includes drugs with recognized medical use but meaningful abuse potential (similar to benzodiazepines and certain sleep medications). That scheduling took effect and remains in place today.
Why the Brand Name Disappeared
Once butorphanol was scheduled as a controlled substance, prescribing became more restricted and tracking requirements increased. The drug’s reputation had also taken a hit. Physicians grew more cautious about writing prescriptions, and the medical community increasingly viewed it as a problematic option for conditions like migraine, where newer and less risky alternatives were emerging.
When a brand-name drug faces declining prescriptions, tighter regulation, generic competition, and reputational damage simultaneously, the manufacturer often makes a straightforward financial decision to stop producing it. That’s what happened with Stadol. The brand was discontinued, but the FDA never revoked approval of the drug itself. Generic butorphanol tartrate nasal spray, manufactured by companies like Apotex, remains available by prescription. It is now distributed under a restricted program called the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy), which adds another layer of safety oversight.
Side Effects That Raised Concerns
Beyond the abuse issue, butorphanol’s side effect profile contributed to its declining popularity. Because of its activity at kappa opioid receptors, it produces a distinct set of neurological effects that go beyond what patients expect from a pain reliever. In clinical trials, commonly reported effects included dizziness, confusion, euphoria, a “floating feeling,” anxiety, and drowsiness. Less common but more troubling reactions included hallucinations, hostility, agitation, abnormal dreams, and withdrawal symptoms.
These effects are sometimes called psychotomimetic, meaning they mimic certain features of psychosis. For a medication prescribed to migraine patients who needed to function in daily life, this side effect profile was a significant drawback, especially as safer alternatives became available.
What Replaced Stadol for Pain and Migraine
The migraine treatment landscape has expanded considerably since Stadol’s peak years. Several classes of intranasal medications now serve the same role with better safety profiles. Sumatriptan nasal spray, available in multiple formulations and doses, became a mainstay. Zolmitriptan is another triptan approved as a nasal spray for patients over 12. Dihydroergotamine, available as the original Migranal spray and the newer Trudhesa formulation, offers another non-opioid option for acute migraine attacks.
More recently, a nasal anti-inflammatory spray (ketorolac, sold as Sprix) provides a completely non-opioid approach to acute pain. And in 2023, the FDA approved zavegepant, the first intranasal CGRP antagonist, representing an entirely new drug class for acute migraine treatment. CGRP antagonists target the specific biological pathway involved in migraine rather than broadly suppressing pain signals, which means fewer neurological side effects.
For patients who previously relied on Stadol, the generic version of butorphanol nasal spray still exists as an option in limited circumstances. But with so many alternatives now available, it occupies a much smaller niche than it did in the 1990s, typically reserved for cases where other treatments have failed or are contraindicated.